94 results about "Gene transcript" patented technology

Systems and methods for targeted gene modification, targeted insertion, perturbation of gene transcripts, and nucleic acid editing. Novel nucleic acid targeting systems comprise components of CRISPR systems and non-LTR retrotransposon elements.

Disclosed herein are UNC13A oligonucleotides with one or more spacers or without a spacer. In various embodiments, UNC13A oligonucleotides with spacer(s) reduce mis-spliced UNC13A transcripts and increase full length UNC13A transcripts, thereby imparting therapeutic efficacy against neurological diseases such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), or Alzheimer's disease (AD).

The present disclosure relates to the field of genetic engineering technology, and more specifically, to a targeting ligand. The targeting ligand provided herein forms a siRNA conjugate with a specific small interfering RNA sequence, which targets ANGPTL3 and degrades ANGPTL3 gene transcripts in cells, thereby reducing ANGPTL3 protein expression. Therefore, the siRNA conjugate formed with the targeting ligand provided herein can be used to prevent and / or treat dyslipidemia.

The present invention provides systems and methods for cell free RNA sequencing. Targeted sequencing can be performed using a set of gene transcripts that are rare abundance in a population of cell free nucleic acid control samples.

The invention discloses a saccharomyces cerevisiae microbiome RNA (Ribonucleic Acid) sequencing data analysis method based on long read length sequencing, which is characterized in that the structure of a gene is updated and optimized by efficiently comparing reference genome data and identifying a new transcript and a new gene transcript of a known gene, so that complete data is provided for analyzing a yeast mRNA (Messenger Ribonucleic Acid) and ncRNA (Non-coding Ribonucleic Acid) structure; and the analysis accuracy and effectiveness are improved.

The application discloses a molecular marker, a primer, a detection method and application related to pig muscle fiber, rib number and back fat thickness, and relates to the technical field of molecular markers. The molecular marker is located in a MYLPF gene, and a sequence of the molecular marker is shown as SEQ ID NO: 4. The sequence is located at a first exon of a 202 transcript of the MYLPF gene, and is used for detecting SNP site mutation. The application determines a cause mutation affecting the circumference, area of pig muscle fiber, rib number and average back fat thickness by using a MYLPF gene promoter constructed to replace a double luciferase reporter vector. A specific primer is designed on the mutation site of the promoter and amplification is performed. The site is detected for polymorphism by using a restriction endonuclease NlaIII. According to the result of the polymorphism detection, differences in the circumference, area of muscle fiber, rib number and average back fat thickness among pig individuals are distinguished, and a large population scale sampling and determination is not needed.

An isolated or purified AON for modifying pre-mRNA splicing in the Receptor for Advanced Glycation End-products (RAGE) to modulate splicing of the RAGE gene transcript or part thereof is provided.

The present invention relates to isolated or purified antisense oligonucleotides that bind to intron 7 of the OPA1 gene pre-mRNA. The present invention also relates to methods for manipulating the translation of OPA1 gene transcripts and to the use of antisense oligonucleotides to treat, prevent or alleviate the effects caused by mutations in the gene OPA1.

An isolated or purified antisense oligomer for modifying pre-mRNA splicing in the CNOT3 gene transcript or part thereof.

Provided herein are methods of determining tumoral sensitivity to hormonal (endocrine) therapy based upon an index of estrogen receptor (ER)- and progesterone receptor (PR)-related genes, referred to as the sensitivity to endocrine therapy index (SETER / PR index), and may have additional consideration for the proportion of ER gene (ESR1) RNA transcripts that contain a mutation relative to the value of the SETER / PR index. Further provided are methods of treating breast cancer patients determined to be sensitive to an endocrine therapy by the SETER / PR index.

The invention discloses a method for identifying cattle red hair color phenotypes by using an 8403bp sequence of an ASIP gene. Three-generation sequencing data of genomes of domestic cattle samples with different hair color phenotypes are analyzed, the 8403bp structural variation sequence of the ASIP gene remarkably related to the red hair color phenotype is identified for the first time, and the sequence is overlapped with an LINE-1 transposon and causes an ASIP gene transcript to generate different mRNA subtypes. By adopting two pairs of primers, detection of the cattle ASIP gene can be realized, and genotyping can be accurately carried out, so that marker-assisted selection can be carried out on cattle red hair color characters on the DNA (Deoxyribose Nucleic Acid) level.

An isolated or purified antisense oligomer (ASO) for modifying pre-mRNA splicing or mRNA translation of one or more of the following proteins encoded by a corresponding gene transcript or portion thereof: S100A8; S100A9; and / or IL1RL2.

An isolated or purified antisense oligomer for use in modifying pre-mRNA splicing in a CNOT3 gene transcript or a portion thereof.

The present disclosure generally relates to a cell-penetrating peptide (CPP) comprising a sequence set forth in SEQ ID NO: 2504 and conjugates thereof. The present invention also relates to antisense oligonucleotides that modulates mRNA productive transcript, stability and / or translation of OPA1 gene transcript or part thereof linked to a cell-penetrating peptide (CPP) comprising a sequence set forth in SEQ ID NO: 2504.

Isolated or purified antisense oligomers, combinations, and cocktails for modifying premRNA splicing or mRNA translation in the SOST gene transcript or a portion thereof to induce downregulation of functional SOST protein production. Isolated or purified antisense oligomers are provided, as needed, for inducing the production of proteins with retained or partially retained introns, truncated proteins, proteins lacking functional regions, or a reduction in the total amount of protein produced.

An isolated or purified antisense oligomer (ASO) for modifying pre-mRNA splicing or mRNA translation in one or more of the following proteins encoded by the respective gene transcript or part thereof S100A8; S100A9; and / or IL1RL2.

An isolated or purified antisense oligomer for modifying pre-mRNA splicing in the CNOT3 gene transcript or part thereof.

The present invention relates to antisense oligonucleotides (ASO) for use in treating, preventing, or ameliorating the progression of conditions such as type 2 diabetes mellitus (T2DM) and insulin resistance, leptin resistance, and obesity, Rater Syndrome, and cancer. Specifically, a thiomorpholino-containing ASO targets a protein tyrosine phosphatase non-receptor type 1 (PTPN1) gene transcript and induces exon skipping (including exon 2) of the transcript during RNA processing, thereby inhibiting expression of the protein tyrosine phosphatase-1B (PTP1B) protein.

The present invention relates to the field of diseases caused by high LDL-C and / or fibrinogen levels, such as cardiovascular diseases. The invention relates to oligonucleotides for RNA (Ribonucleic Acid) editing technology. The oligonucleotides are used for deamination of target adenosine nucleotides, such as 1055th adenosine, in human B4GALT1 gene transcripts.

The application provides a nucleic acid molecule capable of regulating the development of corn female ear and application thereof, the nucleic acid molecule is rGRF16 gene, compared with wild type GRF16 in the corn genome, a synonymous mutation is introduced at the miR396 recognition site of the rGRF16 gene, so that the coding amino acid sequence of the rGRF16 gene is the same as the coding amino acid sequence of the GRF16 gene, and the mRNA transcribed by the rGRF16 gene cannot be recognized and cut by miR396; the nucleotide sequence of the GRF16 gene is shown as SEQ ID NO. 1. By constructing the miR396 insensitive form gene rGRF16 of GRF16, the site-directed base mutation is carried out on the coding sequence of GRF16 based on the codon degeneracy, the mutation modification only changes the target binding sequence of the gene transcript, does not change the coding amino acid sequence, can block the targeted cleavage and degradation of the endogenous miR396 on the transcript of GRF16, and the purpose of overexpression of the GRF16 gene is achieved. By constructing the GRF16 plant of the miR396 insensitive form, the development of the female ear and the grain is significantly promoted, and then the corn yield is improved, and an effective way is provided for the genetic improvement of the corn variety.

Provided herein are altered cell lines comprising a suspension cell line adapted from an adherent cell line having a different expression profile from a corresponding non-altered adherent cell line, methods for generating altered cell lines, and methods of characterizing altered expression profiles for a gene, a transcript, or a protein in an altered cell line.

The present invention relates to the field of genetic engineering technology, and particularly to a method for constructing a mouse model with specific knockout of the Osgep gene in pancreatic islet β cells and its application. The construction method includes the following steps: 1) Determine the knockout region as the exon 2 and exon 3 regions according to the structure of the Osgep gene. The CDS sequence of the Osgep gene transcript is shown in SEQ ID NO.1. Design a gene fragment with flox sites connected at both ends and containing the sequence of the knockout region, and insert this fragment into a plasmid; 2) Design sgRNA according to the upstream sequence and downstream sequence of the knockout region; 3) Mix the sgRNA, Cas9 enzyme and plasmid, and inject them together into the cytoplasm of mouse fertilized eggs to construct edited mouse fertilized eggs and produce F0 generation mice. The present invention discovers through research that Osgep knockout mice can be used for the research of diabetes, and the Osgep gene can play a role in treating diabetic mice.

The present invention discloses a method for screening atypical neoantigens, comprising: an RNA-seq screening step: an HLA typing prediction step: a gene transcript expression quantification step: a transcript variable splicing mutation detection step: an RNA editing mutant peptide generation step; a reference mutant peptide data construction step; a neoantigen prediction step: combining the results obtained in the HLA typing prediction step to obtain the binding affinity of candidate neoantigens to MHC class I and the binding affinity to MHC class II; obtaining atypical neoantigens by sorting candidate neoantigens; the screening method, through RNA-seq data of tumor patients, combined with bioinformatics tools, utilizes the characteristics that effective neoantigens have similar sequences, and shares neoantigens between patients with the same disease.

The invention relates to the technical field of gene engineering, in particular to a construction method and application of a mouse model with an islet beta cell specificity knockout Osge gene. The construction method comprises the following steps: 1) according to the structure of an Osge gene, determining that a knockout region is a second exon region and a third exon region, the CDS sequence of an Osge gene transcript is as shown in SEQ ID NO.1, designing a gene segment of which two ends are connected with flox sites and which comprises a knockout region sequence, and inserting the segment into a plasmid; 2) designing sgRNA according to the upstream sequence and the downstream sequence of the knockout region; and 3) uniformly mixing the sgRNA, Cas9 enzyme and plasmid, injecting the mixture into cytoplasm of the mouse fertilized eggs, and constructing and editing the mouse fertilized eggs to produce F0-generation mice. The research finds that the Osge knockout mouse can be used for researching diabetes, and the Osge gene can play a role in treating the diabetic mouse.

This invention discloses a method utilizing Breast Milk A method for identifying the red coat color phenotype in cattle using an 8403 bp gene sequence. Analysis of third-generation sequencing data from domestic cattle samples with different coat color phenotypes identified, for the first time, a gene significantly associated with the red coat color phenotype. Breast Milk An 8403bp structural variation in the gene sequence overlaps with a LINE-1 transposon, leading to... Breast Milk Gene transcripts produce different mRNA isoforms. This invention achieves the detection of bovine mRNA using two pairs of primers. Breast Milk Gene detection and accurate genotyping can be performed, enabling marker-assisted selection of the red coat color trait in cattle at the DNA level.

Provided are a gene vector, a construction method therefor and the use thereof. The gene vector comprises a sequence as shown in SEQ ID NO. 1, the transcription product of the sequence as shown in SEQ ID NO. 1 comprises a sequence as shown in SEQ ID NO. 2, and the transcription product is not specifically recognized and cleaved by miR529. The transcription product of the gene vector provided by the embodiments is not specifically recognized and cleaved by miR529, which can reduce the degradation of a target gene SPL25 transcript caused by specific recognition and cleavage via miR529, thereby leading to an overexpression of the SPL25 gene in grain crops. The overexpression of the SPL25 gene can increase the number of branches per panicle in grain crops, while having no significant effect on other characters, which is beneficial for the direct use of the gene in genetic improvement and molecular breeding.

The present invention relates to a method for identifying the aging degree of a subject or a tissue or organ thereof, and for evaluating the effect of anti-aging interventions. Specifically, provided is a method for identifying the aging degree of a subject or a cell, tissue or organ thereof, or for evaluating the biological age of the subject or diagnosing premature aging disorders, which method predicts the aging status of a tissue or organ of a subject on the basis of the levels of DNA methylation, gene transcripts, proteins or metabolites. The present invention further relates to the use of metformin in the preparation of a drug for treating, preventing or delaying aging-related diseases or conditions in primates, preferably humans.

The present disclosure generally relates to methods of treating, preventing and / or delaying progression of glaucoma in a subject, the method comprising administering an antisense oligonucleotide that modulates mRNA productive transcript, stability and / or translation of OPA1 gene transcript or part thereof.

Disclosed herein are UNC13A oligonucleotides with one or more spacers or without a spacer. In various embodiments, UNC13A oligonucleotides with spacer(s) reduce mis-spliced UNC13A transcripts and increase full length UNC13A transcripts, thereby imparting therapeutic efficacy against neurological diseases such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), or Alzheimer's disease (AD).

The present invention discloses a method for accurately annotating three generations of full-length transcripts. The method comprises the following steps: obtaining corrected transcript structure information; parsing a human reference genome annotation file, extracting specific gene-transcript information as reference information; parsing the corrected transcript structure information, obtaining preliminary classification information, converting the abnormal transcripts, and obtaining normal data; annotating the normal data, obtaining specific gene-transcript annotations, and final transcript classification information; arranging the annotation information and classification information, and obtaining accurate annotations of three generations of full-length transcripts. Experiments have shown that the accuracy of annotations is significantly improved by annotating three generations of full-length transcripts using the method provided by the present invention. The present invention has important application value.